LLY's 2011Zyprexa expiry vs. PFE's Lipitor expiration
Putting down Mrk, won't help Pfe's PE. I've expained it at length. Ignoring the explanations rather than dealing with them is intellectually dishonest.
Do you disagree that there should be a Kindler discount to PE until and unless the market trusts him to deliver? If so, why?
Same re all the other Pfe distinctive factors I have listed.
When a company like Mrk who was left for dead after the first Vioxx loss by people like Cramer who predicted all time lows does all kinds of right things, it gets the benefit of the doubt going forward. This means a higher PE than Pfe which missed the quarter and has an untested CEO who has expressed no vision about how to deal with replacing major revenue losses (Hint: you don't do it with assumed price increases, at least if you want the market to approve). Pfe is unliked presently with good reason. I come to this conclusion as a long but not one who has lost perspective. Pfe will come back, but my guess is that it will take a new CEO and a major, well-received acquisition before it happens.